salicylsalicylic acid and Cardiovascular Diseases

salicylsalicylic acid has been researched along with Cardiovascular Diseases in 4 studies

salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research

Studies (4)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Change in Systemic Glucose Disposal- Glucose Infusion Rates

Participants were admitted to the Clinical Research Units at 06:00-08:00 hours after an overnight fast. Euglycaemic-hyperinsulinaemic clamps were conducted at baseline and at the end of the study. Because salsalate therapy appears to decrease insulin clearance leading to higher circulating insulin levels during the clamp, we reduced the infusion rate of insulin in the active treatment arm by 20% (from 100 to 80 mUm-2 min-1) at the study end. Insulin solutions were prepared by the site pharmacist so that study staff remained blinded to drug assignment. Whole-body insulin sensitivity was estimated from glucose infusion rate (GIR) during last 30 min of insulin infusions. (NCT00330733)
Timeframe: 3 months

Glucose Area Under the Curve in These Subjects

(NCT00330733)
Timeframe: 3 months

Endothelial Function

Endothelial-mediated arterial responses using peripheral arterial tonometry (PAT; Itamar Medical, Caesarea, Israel). (NCT00330733)
Timeframe: Baseline and 12 weeks

Plasma Adiponectin

Plasma soluble Adiponectin was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Plasma CRP

Plasma C-reactive protein was measured by PVAHS clinical laboratory. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Plasma Interleukin 6

Plasma IL-6 was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Plasma sVCAM

Plasma soluble VCAM was measured by ELISA. Data are reported as change from baseline at 8 and 12 weeks. (NCT00330733)
Timeframe: 8 and 12 weeks

Trials

2 trials available for salicylsalicylic acid and Cardiovascular Diseases

Other Studies

2 other studies available for salicylsalicylic acid and Cardiovascular Diseases